A.3.I. Molecular Imaging Reporter Core (MIRC)The Molecular Imaging Reporter Core is a central facility providing expertise, materials andcollaborative assistance for design and execution of biological aspects of molecular imaging. If one was toidentify the one Core that represented the essence of ICMIC innovation at Washington University, it wouldbe the Molecular Imaging Reporter Core. The MIRC serves investigators possessing a wide range ofresources and experience in molecular biology, cell culture, and animal experimentation. One of the mostimportant activities of this core is discovery research and dissemination of our novel molecular imagingreagents and genetically-encoded reporters to investigators within our institution, to other P50 program sitesand to cancer biology and imaging investigators throughout the world. Discovery research in this Coreprovided the research community with: 1) Novel PET- and bioluminescence-based reporters of proteinproteininteractions in vivo based on modified two-hybrid transcriptional strategies, 2) Novel firefly luciferaseprotein fragment complementation strategies for real-time imaging of protein-protein interactions in vivo, 3)Novel fusion protein strategies for imaging proteasome function in vivo, 4) Innovative platform strategies tointerrogate ubiquitin-induced degradation of ligand-regulated proteins in signaling pathways in real time(e.g., kB, p-catenin and Cdc25A), 5) Second generation fusion reporters and triple-modality reporters formulti-modality imaging (PET/bioluminescence/ fluorescence), 6) Engineered convenient vectors for cloningand expression of click beetle luciferases, firefly luciferase, Renilla luciferase, mtHSV1-TK, mtSSTR-2 andothers for a variety of imaging applications, and 7) Production of transgenic and knock-in molecular imagingreporter mice (e.g., Gal4-Fluc, p21-Fluc, ROSA26-LSL-CGR-mGFP).Indeed, this Core has been and continues to be one of our most productive andcomprehensive activities, discovering and developing novel reporters and impacting a broad rangeof research programs throughout the world. Many investigators within the Washington Universitycommunity as well as outside institutions have directly received material and support from the WU MIRCduring the 5 year period covered by the progress report. These activities include new initiatives,continuation collaborative projects as well as pilot projects that now extend our reach far beyond the focusof the original projects proposed for the Center Program. Overall, as of June 2006, we have distributed ourcollection of molecular imaging reporter reagents and cells to dozens of WU investigators as well as 86investigators throughout the world. Several other P50 ICMIC institutions have requested and received ourcells and reagents, including investigators at the Johns Hopkins University ICMIC (split firefly luciferase,Ub-FLuc plasmid, IkB-FLuc and control plasmids); investigators at the Stanford University ICMIC (IkB-FLuc,FLuc vectors, stable reporter cells expressing IkB-FLuc, coelenterazine analogues); investigators at theUniversity of Michigan ICMIC (split firefly luciferase, Ub-FLuc plasmid); and investigators at Harvard (splitfirefly luciferase, IkB-FLuc). Our most popular reagents (implying high impact) include plasmids encodingour luciferase complementation fragments (split luciferase), IkB-firefly luciferase fusion construct, polyubiquitinated-firefly luciferase, mutant NLS-sr39HSV1-TK-EGFP fusion reporter, and Gal4-firefly luciferasereporter. Publications in high profile journals (e.g., PNAS 2006, 103:1313-1318) have already appeared inthe literature citing us as the source of these molecular imaging reagents for their respective projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA094056-07
Application #
7287034
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (J1))
Project Start
2007-09-28
Project End
2011-12-31
Budget Start
2007-09-28
Budget End
2007-12-31
Support Year
7
Fiscal Year
2007
Total Cost
$275,477
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Murali, Bhavna; Ren, Qihao; Luo, Xianmin et al. (2018) Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Res 78:5618-5630
Miller, Jessica; Wang, Steven T; Orukari, Inema et al. (2018) Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes. J Biophotonics 11:e201700232
Zacharias, Niki; Lee, Jaehyuk; Ramachandran, Sumankalai et al. (2018) Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol :
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858
Hövener, Jan-Bernd; Pravdivtsev, Andrey N; Kidd, Bryce et al. (2018) Parahydrogen-Based Hyperpolarization for Biomedicine. Angew Chem Int Ed Engl 57:11140-11162
Bauerle, Kevin T; Hutson, Irina; Scheller, Erica L et al. (2018) Glucocorticoid Receptor Signaling Is Not Required for In Vivo Adipogenesis. Endocrinology 159:2050-2061
Prudner, Bethany Cheree; Sun, Fangdi; Kremer, Jeffrey Charles et al. (2018) Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas. Theranostics 8:2107-2116
Meinerz, Kelsey; Beeman, Scott C; Duan, Chong et al. (2018) Bayesian Modeling of NMR Data: Quantifying Longitudinal Relaxation in Vivo, and in Vitro with a Tissue-Water-Relaxation Mimic (Crosslinked Bovine Serum Albumin). Appl Magn Reson 49:3-24
Zheleznyak, Alexander; Shokeen, Monica; Achilefu, Samuel (2018) Nanotherapeutics for multiple myeloma. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10:e1526
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494

Showing the most recent 10 out of 283 publications